Reading the adjunct evidence the way a reviewer would The pivotal liraglutide trials, ADJUNCT ONE and TWO, showed HbA1c effects below the regulatory threshold alongside dose-related ketosis and symptomatic hypoglycaemia, and the FDA did not approve liraglutide for type 1 on efficacy and safety grounds.6 The newer story is the automated-insulin-delivery era: ADJUST-T1D paired weekly semaglutide with an AID system in 72 adults with type 1 and obesity, and a composite goal (time in range above 70%, time below range under 4%, and at least 5% weight loss) was met by 36% versus 0% on placebo, with no ketoacidosis.8 Tirzepatide in type 1 rests on a single-centre observational cohort of 26 with no control arm
Readers should verify all details directly with MEDVi, their healthcare provider, and relevant regulatory resources before making decisions
Comparing Tirzepatide to Other Options While tirzepatide is a powerful tool, its part of a broader spectrum of care for obesity
Bioavailability of S-adenosyl methionine and impact on response in a randomized, double-blind, placebo-controlled trial in major depressive disorder
Semaglutide is a GLP-1 receptor agonist that helps people lose weight by: Activating the brains appetite centers to reduce hunger and food cravings
